SG11201903893PA - Synthetic chimeric poxviruses - Google Patents
Synthetic chimeric poxvirusesInfo
- Publication number
- SG11201903893PA SG11201903893PA SG11201903893PA SG11201903893PA SG11201903893PA SG 11201903893P A SG11201903893P A SG 11201903893PA SG 11201903893P A SG11201903893P A SG 11201903893PA SG 11201903893P A SG11201903893P A SG 11201903893PA SG 11201903893P A SG11201903893P A SG 11201903893PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- synthetic chimeric
- pct
- poxviruses
- chimeric poxviruses
- Prior art date
Links
- 241000700605 Viruses Species 0.000 abstract 2
- 241001112285 Berta Species 0.000 abstract 1
- 230000006820 DNA synthesis Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662416577P | 2016-11-02 | 2016-11-02 | |
| US201662434794P | 2016-12-15 | 2016-12-15 | |
| PCT/US2017/059782 WO2018085582A1 (en) | 2016-11-02 | 2017-11-02 | Synthetic chimeric poxviruses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201903893PA true SG11201903893PA (en) | 2019-05-30 |
Family
ID=62075555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201903893PA SG11201903893PA (en) | 2016-11-02 | 2017-11-02 | Synthetic chimeric poxviruses |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11345896B2 (https=) |
| EP (1) | EP3535389A4 (https=) |
| JP (3) | JP2019535311A (https=) |
| CN (1) | CN110431228B (https=) |
| AU (2) | AU2017353868C1 (https=) |
| BR (1) | BR112019008781A2 (https=) |
| CA (1) | CA3042694A1 (https=) |
| IL (2) | IL266399B2 (https=) |
| MX (1) | MX2019005102A (https=) |
| SG (1) | SG11201903893PA (https=) |
| TW (2) | TW202528334A (https=) |
| WO (1) | WO2018085582A1 (https=) |
| ZA (3) | ZA201902868B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019535311A (ja) | 2016-11-02 | 2019-12-12 | デイビッド エバンス， | 合成キメラポックスウイルス |
| US20180228921A1 (en) * | 2017-02-13 | 2018-08-16 | Excision Biotherapeutics, Inc. | Visualizing viral reservoirs and dissemination in vivo |
| EP3788142A4 (en) * | 2018-05-02 | 2022-04-27 | Tonix Pharma Holdings Limited | SYNTHETIC CHIMERIC VACCINE VIRUS |
| US20240024393A1 (en) * | 2019-01-25 | 2024-01-25 | Virocure, Inc. | Pharmaceutical composition for preventing or treating cancer, comprising squirrel fibroma virus and reovirus |
| US20230097513A1 (en) * | 2020-02-03 | 2023-03-30 | City Of Hope | Poxvirus-based vectors produced by natural or synthetic dna and uses thereof |
| KR20220165731A (ko) * | 2020-02-26 | 2022-12-15 | 토닉스 파마 리미티드 | Sars-cov-2 바이러스에 대한 재조합 폭스바이러스 기반 백신 |
| EP4153228A4 (en) | 2020-05-17 | 2024-07-10 | City of Hope | CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS |
| JP2024505274A (ja) | 2021-02-02 | 2024-02-05 | ゲオバックス インコーポレイテッド | ワクチン接種中のｔ細胞プライミングの強化において使用されるウイルスコンストラクト |
| WO2023168286A1 (en) | 2022-03-01 | 2023-09-07 | Tonix Pharmaceuticals Holding Corp. | Recombinant poxvirus based vaccine against the omicron strain of sars-cov-2 virus and variants thereof |
| CN117264909B (zh) * | 2023-10-25 | 2024-11-26 | 深圳湾实验室 | 反式互补缺陷猴痘病毒及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2787577A (en) | 1953-12-01 | 1957-04-02 | Lilly Co Eli | Stable smallpox vaccine |
| US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US6723325B1 (en) | 2001-04-23 | 2004-04-20 | Acambis, Inc. | Smallpox vaccine |
| US20040014034A1 (en) * | 2002-06-06 | 2004-01-22 | Evans David H | Method of producing a recombinant virus |
| WO2005028634A2 (en) | 2003-09-18 | 2005-03-31 | Emory University | Improved mva vaccines |
| JPWO2006022215A1 (ja) | 2004-08-23 | 2008-05-08 | 財団法人ヒューマンサイエンス振興財団 | ＳＡＲＳ−コロナウイルスタンパク質をコードするＤＮＡを保有する組換えワクチニアウイルスＤＩｓ株、およびその利用 |
| CN101020055B (zh) | 2006-02-16 | 2012-08-08 | 中国疾病预防控制中心性病艾滋病预防控制中心 | 基于复制型痘苗病毒载体的sars疫苗 |
| EP2097517B1 (en) | 2006-10-16 | 2014-06-04 | Genelux Corporation | Recombinant Lister strain vaccinia virus encoding an anti-VEGF single chain antibody |
| US8795667B2 (en) * | 2007-12-19 | 2014-08-05 | Macrogenics, Inc. | Compositions for the prevention and treatment of smallpox |
| FI20115914L (fi) | 2011-09-16 | 2013-03-17 | Oncos Therapeutics Ltd | Muunnettu onkolyyttinen virus |
| WO2014160475A1 (en) | 2013-03-13 | 2014-10-02 | Aboody Karen S | Tropic cell based virotherapy for the treatment of cancer |
| WO2014166084A1 (en) | 2013-04-10 | 2014-10-16 | Totbiopharm Shanghai R & D Center | Mutant vaccinia virus strains, uses thereof and method of producing the same |
| EP3045181B1 (en) | 2015-01-19 | 2018-11-14 | Ludwig-Maximilians-Universität München | A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV) |
| CN108135996B (zh) | 2015-08-11 | 2022-06-21 | 卡利迪生物治疗有限公司 | 用以癌症治疗的天花疫苗 |
| AU2017332367B2 (en) | 2016-09-21 | 2021-12-23 | Stephen H. Thorne | High mobility group box i mutant |
| JP2019535311A (ja) | 2016-11-02 | 2019-12-12 | デイビッド エバンス， | 合成キメラポックスウイルス |
| ES2702618B2 (es) | 2017-09-04 | 2019-10-31 | Inst De Salud Carlos Iii | Producto de combinación que comprende una célula madre mesenquimatosa modificada y una sustancia antigénica. |
| CN112261951A (zh) | 2018-05-02 | 2021-01-22 | 通尼克斯制药控股有限公司 | 包含合成嵌合痘苗病毒的干细胞及其使用方法 |
| EP3788142A4 (en) | 2018-05-02 | 2022-04-27 | Tonix Pharma Holdings Limited | SYNTHETIC CHIMERIC VACCINE VIRUS |
-
2017
- 2017-11-02 JP JP2019545700A patent/JP2019535311A/ja active Pending
- 2017-11-02 WO PCT/US2017/059782 patent/WO2018085582A1/en not_active Ceased
- 2017-11-02 MX MX2019005102A patent/MX2019005102A/es unknown
- 2017-11-02 IL IL266399A patent/IL266399B2/en unknown
- 2017-11-02 TW TW113144133A patent/TW202528334A/zh unknown
- 2017-11-02 SG SG11201903893PA patent/SG11201903893PA/en unknown
- 2017-11-02 CN CN201780078546.0A patent/CN110431228B/zh active Active
- 2017-11-02 IL IL319942A patent/IL319942A/en unknown
- 2017-11-02 BR BR112019008781-8A patent/BR112019008781A2/pt active IP Right Grant
- 2017-11-02 AU AU2017353868A patent/AU2017353868C1/en active Active
- 2017-11-02 TW TW106137976A patent/TWI887191B/zh active
- 2017-11-02 EP EP17868045.0A patent/EP3535389A4/en active Pending
- 2017-11-02 US US15/802,189 patent/US11345896B2/en active Active
- 2017-11-02 CA CA3042694A patent/CA3042694A1/en active Pending
-
2019
- 2019-05-07 ZA ZA2019/02868A patent/ZA201902868B/en unknown
-
2022
- 2022-05-06 ZA ZA2022/04981A patent/ZA202204981B/en unknown
- 2022-05-27 US US17/827,320 patent/US12365879B2/en active Active
- 2022-09-02 JP JP2022140113A patent/JP2022164900A/ja not_active Withdrawn
-
2024
- 2024-02-15 AU AU2024200997A patent/AU2024200997A1/en not_active Abandoned
- 2024-05-02 ZA ZA2024/03393A patent/ZA202403393B/en unknown
- 2024-06-10 JP JP2024093677A patent/JP2024107257A/ja active Pending
-
2025
- 2025-06-25 US US19/249,853 patent/US20260022350A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017353868B2 (en) | 2024-02-29 |
| MX2019005102A (es) | 2019-10-30 |
| US20230002741A1 (en) | 2023-01-05 |
| IL266399B1 (en) | 2025-05-01 |
| TW202528334A (zh) | 2025-07-16 |
| IL319942A (en) | 2025-05-01 |
| US11345896B2 (en) | 2022-05-31 |
| TW201819400A (zh) | 2018-06-01 |
| ZA202204981B (en) | 2024-09-25 |
| JP2022164900A (ja) | 2022-10-27 |
| IL266399A (en) | 2019-06-30 |
| IL266399B2 (en) | 2025-09-01 |
| AU2024200997A1 (en) | 2024-03-07 |
| EP3535389A1 (en) | 2019-09-11 |
| US20180251736A1 (en) | 2018-09-06 |
| JP2019535311A (ja) | 2019-12-12 |
| TWI887191B (zh) | 2025-06-21 |
| AU2017353868A1 (en) | 2019-05-16 |
| CN110431228B (zh) | 2024-04-02 |
| BR112019008781A2 (pt) | 2019-07-16 |
| US12365879B2 (en) | 2025-07-22 |
| AU2017353868C1 (en) | 2024-06-06 |
| ZA202403393B (en) | 2025-08-27 |
| CN110431228A (zh) | 2019-11-08 |
| WO2018085582A1 (en) | 2018-05-11 |
| ZA201902868B (en) | 2022-12-21 |
| US20260022350A1 (en) | 2026-01-22 |
| NZ752893A (en) | 2025-10-31 |
| CA3042694A1 (en) | 2018-05-11 |
| JP2024107257A (ja) | 2024-08-08 |
| EP3535389A4 (en) | 2020-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201903893PA (en) | Synthetic chimeric poxviruses | |
| SG11201903042VA (en) | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome | |
| SG11201906795SA (en) | Novel plant cells, plants, and seeds | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201806727TA (en) | Indole and azaindole haloallylamine derivative inhibitors of lysyl oxidases and uses thereof | |
| SG11201809857TA (en) | Anti-CTLA-4 Antibodies | |
| SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201909710XA (en) | Indole ahr inhibitors and uses thereof | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201810509PA (en) | Anti-pd-l1 antibodies | |
| SG11201807279QA (en) | Binding proteins and methods of use thereof | |
| SG11201804729RA (en) | Methods and compositions for treating a serpinc1-associated disorder | |
| SG11201804411TA (en) | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201811446SA (en) | Process for recovering viral products using functionalised chromatography media | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201909584QA (en) | Triterpene saponin analogues | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201909837YA (en) | Methods for treating lung disorders | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof |